Research about Abbvie

Abbvie's Humira has competition in Europe via Biosimilars. The Copies of Humira are selled up to 40% cheaper than Humira itself.

I am going to collect some informations about Abbie here.

Market Cap      121 B
Current P/E      21,99
Forward P/E     9.27
Price/Cashflow 9.86
Dividend           5.32%
Beta                  1.17
Free Cashflow  9.4 B
Dividend Payout Ratio  49% (Source: Seeking Alpha)

Future is important therefore I took a look at the Pipeline.

3 Medicines are in Phase 4
17 are in Phase 3 at the time I read the website www.abbvie.de (02.02.2019)


Outlook from Abbvie: 
We delivered exceptional performance in 2018, including operational revenue growth of more than 15 percent and EPS growth above 40 percent," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We're entering an important new phase for AbbVie. The continued momentum of our business, combined with the launch and ramp of several new products, will allow us to drive strong earnings growth once again in 2019 and position us for growth over the longer term."

Abbvie Chart

Summary:

- Shock about Humira Biosimilars Prices

- EPS Guidance Range of $7.39 to $7.49 2019 compared to $3.66 for 2018

- Abbvie is still growing and a lot of products are in their pipeline.
Therefore I added them into my watchlist.